设计一种针对高风险人类乳头瘤病毒的mRNA疫苗,以利用免疫信息学和动态模拟来向E6和E7coproteins
Md Mijanur Rahman1,2,3, Md Habib Ullah Masum1,2,4, Rehana Parvin5
1Department of Microbiology, Noakhali Science and Technology University, Noakhali, Bangladesh.
PloS one
|January 6, 2025
概括
针对人类乳头瘤病毒 (HPV) 上蛋白E6和E7的两种新型mRNA疫苗在癌症预防方面表现有前途. 计算分析证实了它们的稳定性,免疫性和针对HPV相关癌症的临床开发潜力.
科学领域:
- 疫苗学 疫苗学 疫苗学
- 生物信息学是一种生物信息学.
- 免疫学 免疫学 免疫学
背景情况:
- 人类乳头瘤病毒 (HPV) 类型16和18与几种危及生命的癌症有关,特别是宫癌.
- E6和E7瘤蛋白被确定为HPV诱导瘤发生的关键驱动因素.
- 目前的治疗策略需要创新的方法来预防与HPV相关的癌症.
研究的目的:
- 设计和计算评估两个信使RNA (mRNA) 疫苗 (V1和V2),针对HPV 16/18 E6和E7上蛋白.
- 预测和评估设计疫苗的关键免疫和结构参数.
- 确定这些疫苗在引起针对HPV感染的强有力的免疫反应方面的潜力.
主要方法:
- 生物信息工具被用来识别和选择从HPVcoproteins的T细胞和B细胞表位.
- 位被组装成两个不同的mRNA疫苗结构 (V1,V2) 与链接剂和辅助剂.
- 分析了物理化学性质,二级/三级结构,分子对接,分子动力学模拟和子优化.
- 进行了抗原性,过敏性和毒性评估.
主要成果:
- V1和V2都表现出良好的水友性和令人满意的二级/三级结构,具有高稳定性.
- 对接分析显示,对Toll类受体2和4具有显著的结合亲和力.
- 分子动力学模拟证实了结构完整性,子优化预测了大肠杆菌的高表达水平.
- 这些疫苗成功地引起了显著的B细胞和T细胞反应,表明了持续天生的和适应性免疫的潜力.
结论:
- 针对HPVcoproteins的设计的mRNA疫苗 (V1和V2) 显示出有希望的物理化学和免疫特性.
- 计算评估表明这些疫苗是稳定的,免疫的,并具有显著的临床进步潜力.
- 需要进一步的体外和体内研究来验证这些新型HPV疫苗的疗效.
相关概念视频
Initiation of Translation
30.6K
Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
30.6K
Cancer Vaccines
337
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
337


